111, Inc. and Scrianen Pharmaceutical Co. Partner for Healthcare Innovation

On June 11, 2024, 111, Inc., a leading tech-enabled healthcare platform company in China, announced a significant partnership with Beijing Scrianen Pharmaceutical Co., Ltd. This strategic collaboration focuses on enhancing the distribution of healthcare products, including the widely recognized 'Scrianen Folic Acid Tablets' across China.

Since 2017, 111 has been actively involved in Scrianen's Authentic Alliance, and this new direct supply partnership aims to strengthen their retail market cooperation. By leveraging big data, digital marketing, and cloud services, both companies are committed to improving drug accessibility both online and offline.

111 has established an integrated online and offline healthcare ecosystem, offering services such as '1 Pharmacy', '1 Clinic', '1 Medicine', and a '1 Health Membership program'. With partnerships with over 500 domestic and international pharmaceutical companies, 111 is dedicated to empowering stakeholders in the healthcare industry.

Scrianen, a renowned pharmaceutical enterprise, specializes in various healthcare areas, including reproductive health, maternal and child health, orthopedics, oncology, gynecology, pediatrics, and geriatric diseases. Their flagship product, 'Scrianen Folic Acid Tablets', has gained international recognition and is listed in the Chinese Pharmacopoeia.

The partnership between 111, Inc. and Beijing Scrianen Pharmaceutical Co., Ltd. signifies a significant step towards reshaping the healthcare industry in China. Through their combined efforts, they aim to provide better access to pharmaceutical products and healthcare services through innovative online and offline platforms.

The collaboration between 111, Inc. and Scrianen Pharmaceutical Co., Ltd. marks a milestone in the healthcare sector, promising improved distribution of essential healthcare products. This partnership reflects a commitment to enhancing healthcare accessibility and services for the benefit of the Chinese population.